Cancer cell international · 2026
Serum N-glycan NA3Fb identified as a prognostic biomarker of poor outcome in HBV-related hepatocellular carcinoma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kang Pengyuan, Wang Min, Liu Jie, Wang Jiang, Li Xinjie, Jiang Bo, Lin Rui, Zhong Siqi, Xu Lei, Chen Cuiying, Li Bo, Shen Tao
Аннотация
BACKGROUND: Glycosylation, as one of the most prevalent forms of post-translational modification, plays a pivotal role in tumor progression through structural alterations of serum N-glycans in hepatocellular carcinoma (HCC). In this study, we systematically investigated these N-glycan profiles as potential prognostic biomarkers for predicting patient survival outcomes.
METHODS: This study enrolled a cohort of 150 hepatitis B virus (HBV)-related HCC patients (BCLC stages A-D) who received treatment and follow-up monitoring at Southwest Medical University Hospital from 2022 to 2023. Additionally, 105 chronic hepatitis B (CHB) patients, 50 healthy individuals matched for age and gender were recruited as controls. Serum N-glycan profiles were characterized using capillary gel electrophoresis laser-induced fluorescence detection (CGE-LIF).
RESULTS: The relative intensities (RIs) of Peak 9 (NA3Fb) was specifically elevated in HBV-related HCC patients. This peak emerged as an independent predictor of survival (p = 0.004), strongly correlated with advanced tumor stage (p < 0.01), and it was associated with HBsAg loss following anti-PD-1 therapy. MGAT4A, the gene implicated in regulating Peak 9, is likely significantly involved in critical pathways driving HCC progression.
CONCLUSIONS: Serum N-glycan profiling represents a promising noninvasive tool for monitoring prognosis and outcomes in HCC patients. Peak 9 (NA3Fb) was identified as a prognostic biomarker significantly associated with clinical outcomes in HBV-related HCC.
METHODS: This study enrolled a cohort of 150 hepatitis B virus (HBV)-related HCC patients (BCLC stages A-D) who received treatment and follow-up monitoring at Southwest Medical University Hospital from 2022 to 2023. Additionally, 105 chronic hepatitis B (CHB) patients, 50 healthy individuals matched for age and gender were recruited as controls. Serum N-glycan profiles were characterized using capillary gel electrophoresis laser-induced fluorescence detection (CGE-LIF).
RESULTS: The relative intensities (RIs) of Peak 9 (NA3Fb) was specifically elevated in HBV-related HCC patients. This peak emerged as an independent predictor of survival (p = 0.004), strongly correlated with advanced tumor stage (p < 0.01), and it was associated with HBsAg loss following anti-PD-1 therapy. MGAT4A, the gene implicated in regulating Peak 9, is likely significantly involved in critical pathways driving HCC progression.
CONCLUSIONS: Serum N-glycan profiling represents a promising noninvasive tool for monitoring prognosis and outcomes in HCC patients. Peak 9 (NA3Fb) was identified as a prognostic biomarker significantly associated with clinical outcomes in HBV-related HCC.